Brief: Precigen Announces Positive Phase 1 Data For PRGN-3005 Autologous UltraCAR-T Cells
05/06/2023 21:40
June 5 (Reuters) - Precigen Inc PGEN.O :
* PRECIGEN ANNOUNCES POSITIVE PHASE 1 DATA FOR PRGN-3005
AUTOLOGOUS ULTRACAR-T® CELLS MANUFACTURED OVERNIGHT FOR INFUSION
NEXT DAY TO ADVANCED STAGE PLATINUM RESISTANT OVARIAN CANCER
PATIENTS
* PRECIGEN INC - PRGN-3005 WAS WELL-TOLERATED WITH NO DOSE
LIMITING TOXICITIES, NO CRS GREATER THAN GRADE 2, AND NO
NEUROTOXICITY
Source text for Eikon: ID:nPnb5KJlYa
Further company coverage: PGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precigen
See all newsBrief: Precigen Receives FDA Platform Technology Designation For Adenoverse Platform
Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Precigen posts quarterly profit as PAPZIMEOS sales surge
Precigen Inc expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras